Faecal calprotectin and magnetic resonance imaging in detecting Crohn’s disease endoscopic postoperative recurrence

Table 1 Characteristics at the time of endoscopy of the 30 patients with Crohn’s disease enrolled in this study n (%)

Patients’ characteristics	Value
Age at diagnosis, (yr), mean ± SD	34.9 ± 14.1
Disease duration, (yr), mean ± SD	9.0 ± 9.5
Female gender	15 (50.0)
Active smokers	7 (23.3)
Montreal classification
CD location
L1	15 (50.0)
L2	1 (3.3)
L3	14 (46.7)
CD behaviour
B1	1 (3.3)
B2	16 (53.3)
B3	13(43.3)
Perianal lesions	7 (23.3)
Therapy to prevent endoscopic POR1
None	6 (20.0)
5-ASA	2 (6.7)
Thiopurines	17 (56.7)
Anti-TNF agent	6 (20.0)
CDAI, median (interquartile range)	78 (26-86)
CRP, median (interquartile range)	2.9 (2.9-3.9)
Faecal Calprotectin (μg/g), median (IQR)	100 (100-136)

¹The patients were treated with one or several of these medications. CD: Crohn’s disease; POR: Postoperative recurrence; TNF: Tumor Necrosis Factor; CDAI: Crohn’s disease activity index; CRP: C-reactive protein.